Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- ChecktodayChange DetectedThe Publications section, including the PubMed-listed article and the auto-fill note about PubMed entries, has been removed from the study page. This reduces visible references and attribution for the study without altering core trial details.SummaryDifference0.2%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe page's revision tag changed from v3.6.2 to v3.6.3, indicating an updated version of the page. This update does not modify the core study details or user-facing content beyond the version label.SummaryDifference0.0%

- Check22 days agoChange DetectedPage revision updated from v3.6.0 to v3.6.2, representing a newer version of the page's template or metadata. No substantive study details, eligibility criteria, or results appear to be changed.SummaryDifference0.0%

- Check29 days agoChange DetectedLinks and metadata for study documents were added, including PDF versions of the Statistical Analysis Plan and Study Protocol, along with notes on IPD plans and related MeSH terms. These updates provide researchers with direct access to the study's methodology and regulatory context.SummaryDifference63%

- Check36 days agoChange DetectedRevision: v3.6.0 was added. Several study documents and metadata (PDFs, protocols, IPD plans, collaborators) were removed from the study record.SummaryDifference18%

- Check43 days agoChange DetectedThe page shows a revision update from v3.5.4 to v3.5.5, representing an internal software or content-management update. This does not alter the information presented about the study or its navigation.SummaryDifference0.0%

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.